Clinical study of anti-vascular endothelial growth factor(VEGF) therapy
| Project/Area Number |
23591608
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Embryonic/Neonatal medicine
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 未熟児網膜症 / 光凝固 / 硝子体手術 / 低出生未熟児 / 抗VEGF抗体 / 抗ＶＥＧＦ薬 / 低出生体重児 |
|---|
| Outline of Final Research Achievements |
Twenty two eyes of eleven cases with retinopathy of prematurity (ROP) were treated by intravitreal ranidizmab injection (IVR). Average post-conceptual age at birth was 23.9 weeks and average birth weight was 653 gr. Sixteen eyes (73%) have aggressive posterior ROP (APROP) or zone I ROP, and six eyes (27%) have zone II ROP. Average gestational age at IVR was 32.6 weeks. Temporal regression and reactivation were seen on all of eyesAdditional treatment required on eight eyes (50%) with APROP or zone I ROP.
The results were compared with thirty four eyes of seventeen eyes treated by intra vitreal bevasizumab injection (IVB). No significant difference was observed between IVR treated eyes and IVB treated eyes on post-conceptual age at birth, birth weight, gestational age at initial treatment, temporal regression rate, reactivation rate, additional treatment rate and final outcome. Plasma VEGF concentration reduced at one week after IVR, and tended to recover at two weeks following IVR.
|
Report
(5 results)
Research Products
(19 results)
